Ranked by shared topics, with one result from each original episode.
“In this Aliquot, I explain why visceral fat behaves so differently from other fat, how it drives insulin resistance and chronic disease, and what research shows about the most effective ways to reduce it.”
“In this Aliquot, I walk through how that plays out in humans, where the strongest evidence shows up, and where it doesn't, with NAD researcher Dr. Charles Brenner—and why I'm taking it now after being skeptical.”
“Modulating autophagy – through fasting and exercise (which both increase acetyl CoA) or intake of nutrients like spermidine – represents a promising therapeutic approach for extending human lifespan and healthspan.”
“It has attracted interest for its potential to activate mitophagy, the process cells use to clear out damaged mitochondria. In this Aliquot, I explain why mitochondrial cleanup matters for aging, why urolithin A production varies, and what early human studies suggest about its potential benefits.”
“Because some long-chain PFAS travel through a similar pathway, researchers are now asking whether beta-glucans might also help the body eliminate these persistent "forever chemicals."”
“A more useful approach is to focus on what you can do to reduce its effects. In this Aliquot, Dr. Kelly Starrett explains why standing more is not enough, how to build movement into your workday, and why it matters for long-term mobility.”
“The timing of eating and exercise, especially in elite athletes, hasn't been studied and may, in fact, require self-experimentation by the athletes to identify the perfect interval of fasting to support their optimal performance.”
“But exercise — especially intense exercise — can also help to manage the symptoms once the disease develops. These Aliquot segments feature Dr. Giselle Petzinger, a board-certified neurologist who specializes in the care of patients with Parkinson's disease.”
“Recent discoveries in the field of epigenetics suggest we might be able to slow aging, based on the realization that not everyone ages at the same rate. Evidence suggests that drugs or other medical procedures can slow epigenetic aging, but other factors, such as diet and disease states influence it too.”
“And one potential strategy for mitigating our risk for Alzheimer's disease as we age is a "cognoscopy" – a battery of assessments that measures some of the key biomarkers associated with the disease and can inform the trajectory of treatment.”